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Background: A cost-effective, accurate and rapid simultaneous multiplex assay is required for testing and diagnoses
of conventional and emerging viruses in clinical virology laboratories. We developed and optimized a dual priming
oligonucleotide (DPO) multiplex PCR assay for detecting influenza viruses including seasonal H1N1, 2009 pandemic
H1N1, H3N2, influenza B and H5N1.
Methods: The optimized multiplex DPO PCR was used to detect 233 clinical human samples. The results were
compared to those obtained with RT-qPCR, conventional PCR and immunochromatographic assay.
Results: Specificity analysis revealed that the DPO PCR assay amplified each target virus without any cross-
amplification. Statistical analysis demonstrated that the multiplex DPO-PCR sensitivity was higher than for the
immunochromatographic assay and lower than for qPCR, while no significant difference was observed compared
with conventional PCR, when detecting influenza A and B. Additional experiments using the same sample panel
indicated no significant differences between the number of positive samples detected by multiplex DPO PCR and
RT-qPCR when applying a Cq with a value lower than 30.
Conclusions: The five-targeted simultaneous multiplex DPO PCR assay could be easily adopted into routine
practice. This approach is cost effective with a short running time, low technical requirements for the detection of
influenza virus and early diagnosis in clinical laboratories.
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Influenza viruses are the major pathogens causing res-
piratory diseases with severe morbidity and mortality
worldwide [1]. Novel and recombinant strains of influenza
viruses have caused pandemics resulting in millions of
deaths. The rapid detection of these viruses is essential for
a medical response and infection control [1]. A low-cost
and rapid identification of influenza types and subtypes in
clinical patients is essential for initial clinical treatment
and avoidance of antibiotic misuse, as well as prevention* Correspondence: hukongxin@caiq.gov.cn
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limited regions [1].
Molecular assays are highly sensitive and specific for
detecting influenza viruses such as rapid immune colloidal
gold diagnostic tests, immunofluorescence, enzyme-linked
immunosorbent assay (ELISA) and viral culture. Nucleic
acid based tests for respiratory viruses are currently used
as a rapid and sensitive diagnostic approach for clinical
specimens. A cost-effective, accurate and rapid multiplex
assay is highly desirable in clinical virology laboratories for
testing and diagnosing common and emerging viruses.
Even though the multiplex real time polymerase chain re-
action (PCR) is a rapid and sensitive method for the detec-
tion of respiratory viruses, such assays are limited to a
maximum of four multiplexed targets, and the high costs is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for laboratories with low financial constraints [2].
Therefore, a novel dual priming oligonucleotide (DPO)
technology was developed to solve these problems. The
DPO primer contains two separate priming regions joined
by a polydeoxyinosine linker, which assumes a bubble-like
structure not involved in priming, but which delineates
the boundary between two regions of the primer [3]. This
structure confers distinct annealing properties on the two
primer segments. The longer 5′-segment initiates stable
priming, while the short 3′-segment determines target-
specific extension [3]. The advantage of DPO based PCR
is the blocking extension of non-specifically primed tem-
plates under less than optimal PCR conditions [3]. DPO
technology was commercialized and used in many recent
studies to test different respiratory viruses [3]. Addition-
ally, several studies have compared DPO based multiplex
PCR with other rapid methods for the detection of influ-
enza viruses. The results suggested that the DPO based
multiplex PCR system had a higher sensitivity and specifi-
city than the other methods tested [4-7]. However, most
of these recent studies, including those using commercial
DPO based rapid detection kits, tested numerous different
respiratory viruses or different types of influenza viruses.
Only one commercial kit (Seeplex® Influenza A/B OneStep
Typing, Seegene, Seoul, Korea) can simultaneously detect
influenza A, B and subtypes of influenza A including
2009 pandemic H1 and Human Seasonal Influenza A (H1
and H3). Recently, the live poultry market has posed a
high risk for human infection following the avian infection
in Beijing, China [8]. The highly pathogenic avian influ-
enza H5N1 was identified in local poultry and wild birds
is enzootic in China [8]. Therefore, it is important to de-
velop a rapid and simple method to detect avian influenza
viruses. To our knowledge, no previous study has reported
the development of a DPO multiplex assay for the simu-
ltaneous detection of influenza A, B and subtypes of in-
fluenza A including H5N1.Table 1 DPO primers used for multiplex DPO PCR
Virus Target gene Primer sequ










HA: hemagglutinin gene; PB1:polymerase basic 1 gene; F: forward primer; R: reverseThe purpose of this study was to develop and optimize
a DPO multiplex PCR assay for detection of influenza A
and B viruses, including the influenza A subtypes, such
as seasonal H1N1, 2009 pandemic H1N1, H3N2, and
avian influenza H5N1. Additionally, the study compared
and evaluated DPO PCR, qPCR, conventional PCR and
immunochromatographic assay for the detection of in-
fluenza viruses in clinical specimens.Methods
Clinical samples
This study randomly screened 233 clinical specimens
from feverish patients including human oropharyngeal
swabs, nasopharyngeal swabs and sputum from Chinese
Academy of Inspection and Quarantine, Center for Di-
sease Control of China, Beijing, China and the Shenzhen
International Travel Health Care Center. Two H5N1 spec-
imens were obtained from avian species from the Center
for Disease Control of China. Additionally, 59 respira-
tory samples including parainfluenza viruses 1/2/4 (PIV1/
2/4), human rhinovirus (HRV), human metapneumovirus
(hMPV), adenovirus (ADV), coronavirus 229E (CoV229E),
respiratory syncytial virus A/B (RSV A/B) and bocavirus
(BoV) were collected to assess the specificity of the multi-
plex DPO assay.DPO primer design
DPO is a primer system for PCR that contains a bubble-
like polydeoxyinosine linker that separates a single pri-
mer into two unequal regions. The five influenza virus
sequences were aligned by MEGA5.1 [9]. Five pairs of
DPO primers were designed based on the specific regions
for each virus (Table 1). The optimal numbers of poly-
deoxyinosine for each DPO primer was determined by
testing 3–8 poly (I) linkers for each target virus. The amp-
lified products were analyzed by 2.0% agarose (Biowest,











primer; bp: base pair.
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All clinical samples were concentrated and enriched by a
virus concentration device to increase the virus load.
Viral RNA was extracted from viral solutions using the
QIAamp Viral RNA Mini Kit (Qiagen, Germany) following
the manufacturer’s specifications. A volume of 140 μl of
virus solution was mixed with 560 μl buffer AVL-carrier
RNA and incubated for 10 min at room temperature. After
adding 560 μl ethanol (100%), the solution was mixed thor-
oughly by pulse-vortexing and then transferred to a spin-
column. After a series of washing and drying steps, 60 μl of
RNase-free water was used to elute RNA, which was stored
at −70°C. The master mix for reverse transcription was
prepared using a reverse transcription system (Promega,
USA) under the following conditions: a mixture of 5 μl
RNA template, 1 μl Random primer and 2 μl RNase-free
water was denatured at 95°C for 2 min and cooled on ice
for 2 min. Then 4 μl of MgCl2 (25 mM), 2 μl dNTPs
(10 mM), 2 μl reverse transcription 10× buffer, 30 U of
AMV reverse transcriptase, 25 U of RNasin ribonuclease
inhibitor and nuclease-free water were added to a final vol-
ume of 20 μl. Subsequently, the mixture was incubated at
42°C for 90 min and 72°C for 10 min. Finally, the cDNA
was stored at −20°C.
Multiplex DPO PCR protocol
Multiplex DPO PCR reactions contained 1.5 U of Takara
Taq (Takara Bio, Dalian, China), 2.5 μl of 10× PCR buffer,
2.0 mM Mg2+ and 250 μM dNTPs. The optimal concen-
tration of DPO primer mix are listed in Table 2. 2009 pan-
demic H1N1, seasonal H1N1, H3N2 and H5N1 primers
at a concentration of 0.8 μM and influenza B primers at a
concentration of 1.6 μM, 2 μl cDNA and nuclease-free
water were added to a total volume of 25 μl. The amplifi-
cation conditions of the multiplex PCR were as follows:
pre-denaturation step for 5 min at 94°C, 40 cycles of de-
naturation at 94°C for 30 s, annealing at 60°C for 30 s, ex-
tension at 72°C for 1 min, followed by a final extension
step at 72°C for 10 min. The multiplex DPO PCR was per-
formed with an Applied Biosystems® 2720 Thermal Cycler
(Life Technologies, NY, USA). The amplified products
were analyzed by 2.0% agarose gel electrophoresis.
Analytical sensitivity and specificity
The partial HA and PB1 gene sequences of each virus





H3N2 H5N1 Influenza B
Forward Primer (μM) 20 20 20 20 40
Reverse Primer (μM) 20 20 20 20 40
25× primer mix (μM) 0.8 0.8 0.8 0.8 1.6H1N1, CY087016, nt 616–846; H3N2, CY091581, nt
96–632; H5N1, AB598119, nt 210–537; influenza B,
CY069569, nt 955–1355) were synthesized and inserted
into pGM-T (Tiangen, China) to construct five specific
plasmids. These plasmids were then in vitro transcribed
using the RiboMax™ Large Scale RNA Production System-
T7 according to the manufacturer’s instructions (Promega,
USA). The RNA concentration were detected by spec-
trophotometer (NanoDrop, Delaware, USA) and then
reverse-transcribed to cDNA as previous instruction
(Promega, USA). The initial concentration of sH1N1,
H1N1pdm09, H3N2, H5N1 and FluB were 1.3 × 1011
copies/ml, 5.7 × 1010 copies/ml, 6.2 × 1010 copies/ml, 1.3 ×
1010 copies/ml and 3.5 × 1010 copies/ml, respectively.
A ten-fold serial dilution of plasmid DNA was used to
compare the sensitivity levels of the multiplex PCR and
the single conventional PCR for amplifying each type of
influenza. Then, a pooled solution of all five templates
was diluted in series (107–101 copies/ml), and detected
by multiplex DPO primers to determine the sensitivity.
The specificity test comprised the five pooled templates
amplified by each pair of DPO primers individually. Add-
itionally, the measurement of one-step multiplex DPO
PCR specificity was determined using eight respiratory
viral RNA preparations: PIV1/2/4, HRV, hMPV, ADV,
CoV229E, RSVA, RSVB and BoV.
Sequencing
The amplified conventional PCR products were sequenced
to evaluate the specificity of the assay. Sequencing was
performed using an ABI PRISM 3730 DNA Sequencer
and sequences obtained were confirmed by the GenBank
(National Center for Biotechnology Information) database
with the Basic Local Alignment Search Tool (BLAST).
RT-qPCR
Total RNA from 140 μl clinical samples was separately
extracted using QIAamp Viral RNA Mini kit (Qiagen,
Valencia, CA, USA). RNA was eluted in 60 μl of elution
buffer and stored at −80°C. The singleplex RT-qPCR was
performed using an Applied Biosystems® 7500 Real-Time
PCR System (Applied Biosystems® by Life Technologies,
NY, USA) to test all clinical samples. The primers and
probes used for the RT-qPCR were suggested by WHO
Information for Molecular Diagnosis of Influenza Virus
in Humans - update (November 2012) [10]. RT-qPCR
was performed with an AgPath-ID™ One-Step RT-PCR
Kit (Ambion, Applied Biosystems® by Life Technologies,
NY, USA). A total of 25 μl RT-qPCR mixture included
12.5 μl of 2× RT-PCR buffer, 1 μl 25× RT-PCR enzyme
mix, 0.5 μl one-step RT-PCR master kit (Qiagen),
0.5 μl (20 μM) of each primer, 0.3 μl (10 μM) of probe,
4.7 μl of nuclease-free water and 5 μl of extracted RNA.
The thermocycling parameters were as follows: reverse
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at 95°C for 10 min and fluorescence detection for 40
cycles at 95°C for 15 sec and annealing at 60°C for
45 sec. RT-qPCR data was analyzed by SDS software
from Applied Biosystems®. Amplification curves were
evaluated by the threshold line being placed above the
background signal, intersecting the initial exponential
phase of the curve. Amplification of influenza virus was
observed at a quantification cycle (Cq) value of 35. A
test result was considered positive when a well-defined
curve that crossed the threshold cycle within 35 cycles
was observed.Conventional PCR protocol
The detection kit used in our study was from Takara
Biotechnology (Dalian) Co., Ltd. A 25 μl reaction system
was set up containing 2 μl template RNA, 0.125 μl
Takara Taq (250 U/μl), 0.5 μl of each primer (10 μM),
2 μl of 10× PCR Buffer (Mg2+ Plus), dNTP mixture
(2.5 mM) and 17.4 μl RNase free water. The test was
performed using a Applied Biosystems® 2720 Thermal
Cycler. The PCR reaction was amplified under the fol-
lowing conditions: pre-denaturation step for 5 min at
94°C, 40 cycles of denaturation at 94°C for 30 s, an-
nealing at 60°C for 30 s, extension at 72°C for 1 min,
followed by a final extension step at 72°C for 10 min.
The PCR was performed by Applied Biosystems® 2720
Thermal Cycler. The amplified products were analyzed
by 2.0% agarose gel electrophoresis.Alere BinaxNOW® Influenza A&B Card rapid detection assay
The colloidal gold immunochromatographic assay was
applied for the detection of influenza A and B. The pro-
cedure followed the manufacturer’s instructions.Comparison of multiplex DPO, conventional and RT-qPCR,
and Alere BinaxNOW® Influenza A&B Card rapid detection
assay for influenza A and B
All clinical specimens were screened for seasonal H1N1,
2009 pandemic H1N1, H3N2, influenza B and avian in-
fluenza H5N1 by multiplex DPO PCR. RT-qPCR and
conventional PCR for the detection of influenza A and
B were used to validate the multiplex DPO PCR method
and results were compared to those obtained by immuno-
chromatographic assay.Figure 1 Optimized number of poly (I) linkers in DPO primer
design for sH1N1, H1N1pdm09, H3N2, H5N1 and FluB by
multiplex DPO PCR. Lane 1: negative control; Lane 2–7: three to
eight polydeoxyinosine (I) linkers in DPO primers tested for each
target virus; Lane M: DNA marker.Statistical analysis
Statistical analysis was performed by SPSS18.0 (IBM, New
York, USA). The chi-squared test was used to analyze
data and a P value of < 0.05 was considered statistically
significant.Ethical statement
The study was conducted according to the protocol
approved by the Human Research Ethics Committee,
Chinese Academy of Inspection and Quarantine in com-
pliance with the provisions for human research in the
Helsinki Declaration (ES-0823696/2014/376HQ). Written
informed consent was obtained from all the participants.
Results
Optimized numbers of poly I linkers in DPO primer
design and annealing temperature for multiplex DPO PCR
The number of poly (I) in DPO primers impacts both
the sensitivity and specificity of the DPO PCR amplifica-
tion. This study therefore tested various numbers of poly
(I) linkers, with five linkers proving optimal (Figure 1).
Because the influenza viral gene are highly mutable, four
annealing temperatures (Tm) were selected and applied
to different concentrations of the mixed templates. When
the Tm was 46°C and 50°C, the lowest template con-
centration was 104 viral particles/ml (Figure 2). When
the Tm was increased to 55°C, faint bands (103 viral
particles/ml) were observed. When the Tm reached to
60°C, distinct bands indicated the lowest concentration
of mixed template was 103 viral particles/ml for multi-
plex DPO PCR.
Multiplex DPO PCR sensitivity
A 10-fold dilution series was used to determine the
lowest concentration detected by the multiplex DPO
PCR. This was found to be 103 copies/ml for sH1N1,
H1N1pdm09, H3N2, H5N1 and FluB; although very
faint bands were also observed in lane 6 for 102 viral
particles/ml (Figure 3). The sizes of the amplified pro-
duct were detected by 2% agarose gel, and determined
to be 537 bp for H3N2, 401 bp for FluB, 328 bp for
H5N1, 231 bp for H1N1pdm09, and 193 bp for sH1N1.
Although a pooled mixture of the five virus templates
was used for amplification by the multiplex primers, no
cross-amplification was observed.
Figure 2 Optimized annealing temperature for sH1N1, H1N1pdm09, H3N2, H5N1 and FluB by multiplex DPO PCR. (A: Tm = 46°C;
B: Tm = 50°C; C: Tm = 55°C; D: Tm = 60°C). Lanes: M: DNA Marker; 1–6: 107–102 viral particles/μl. 537 bp for H3N2, 401 bp for FluB, 328 bp for
H5N1, 231 bp for H1N1pdm09, and 193 bp for sH1N1.
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A single pair of DPO primers was used to amplify sH1N1,
H1N1pdm09, H3N2, H5N1 and FluB mixture to test the
assay specificity. Each primer set produced a single ampli-
fied band without non-specific amplification (Figure 4A).
Additionally, the multiplex PCR primers were used to
amplify each target virus template. Agarose gel analysis
confirmed the multiplex PCR amplification for each
lane containing sH1N1, H1N1pdm09, H3N2, H5N1 and
FluB, respectively (Figure 4B). No amplification was ob-
served for PIV1/2/4, HRV, hMPV, ADV, CoV229E, RSVA,
RSVB or BoV when using the multiplex DPO primers
(Figure 4C).
Screening of clinical specimens by multiplex DPO PCR
Using singleplex RT-qPCR as a standard, the overall
positives were 153. Of 153 positive specimens, 84 were
identified as influenza A and 69 as influenza B. Figure 5
shows the selected multiplex DPO PCR result for clinicalFigure 3 Detection sensitivity of sH1N1, H1N1pdm09, H3N2, H5N1 an
viral particles/ml; 9: negative control. 537 bp for H3N2, 401 bp for FluB, 328sample detection. The percentage of influenza A and B
positive samples detected by multiplex DPO PCR in con-
cordance with real time RT-PCR was 66.67% and 62.32%,
respectively (Table 3).
DPO PCR positive influenza A and B specimens were
assessed and confirmed by sequencing to prevent false-
positive or false-negative results.
Comparison of different methods for the detection of
influenza A and B
Multiplex DPO PCR, RT-qPCR, conventional single-target
PCR and commercial colloidal gold immunochromato-
graphic assay Alere BinaxNOW® Influenza A&B Card
(Alere, CA, USA) were used to detect influenza A and B.
The selected test results for qPCR and immunochromato-
graphic assay are shown in Figures 6 and 7, respectively.
The order of positive detection efficiency from highest to
lowest was RT-qPCR, multiplex DPO PCR, conventional
PCR and immunochromatographic assay (Figure 8). Thed FluB by multiplex DPO PCR. Lanes: M: DNA Marker; 1–8: 107–101
bp for H5N1, 231 bp for H1N1pdm09, and 193 bp for sH1N1.
Figure 4 Detection specificity of sH1N1, H1N1pdm09, H3N2, H5N1 and FluB by multiplex DPO PCR. A: Each of the five primer pairs
was applied individually to amplify a pooled mixture of the five different target cDNAs (Lanes 1–5: sH1N1, H1N1pdm09, H3N2, H5N1 and FluB,
respectively). B: A pooled mixture of the five primer pairs was applied to each of the five target cDNAs individually for amplification (Lanes 1–6:
sH1N1, H1N1pdm09, H5N1, FluB, H3N2 and negative control). C: Detection of other respiratory viruses (Lanes 1–12: positive control, PIV1, PIV2,
PIV4, HRV, hMPV, ADV, CoV229E, RSVA, RSVB, BoV and negative control).
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sH1H1, H1N1pdm09, H3N2, H5N1and FluB are shown
in Figure 9. Multiplex DPO PCR displayed 70% correl-
ation with qPCR positive results for influenza A, while in-
fluenza B results showed lower correlation with qPCR.
qPCR positive results that were inconsistent with multi-
plex DPO PCR samples were selected for further testing
and the expected Cq was recorded. Figure 10 shows that
different numbers of positive samples were observed for
DPO PCR and RT-qPCR when using three different
ranges of Cq values. When Cq was less than 25 or in the
range of 25–30, no difference was observed between DPO
and qPCR in terms of the number of positive samples
detected. When the Cq value was between 30 to 35, the
number of positive results obtained by qPCR were
greater than those for DPO PCR.Statistical analysis of different detection methods
Statistical analysis showed that the sensitivity of the
multiplex DPO assay was lower than for qPCR (P <0.05),
higher than for the colloidal gold immunochromato-
graphic assay (P <0.05), but not significantly different
from conventional PCR (P >0.05) (Figure 8). When the
Cq value was lower than 30, no significant difference
between multiplex DPO PCR and qPCR when compar-
ing the positive results (Figure 10).
Discussion
A rapid, accurate and low-cost diagnostic tool for
influenza detection is important for the control and
prevention of annual influenza pandemics. A previous
study described the development of a multiplex DPO
PCR assay for the simultaneous and specific detection
Figure 5 The selected result of clinical samples by multiplex DPO PCR. Selected 85 screening result for influenza A and B detection using
multiplex DPO PCR. Lane M: DNA marker; lane P: positive control; lane N: negative control.
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optimization of one-step multiplex DPO PCR for use
as a sensitive and specific method to detect seasonal
H1N1, 2009 pandemic H1N1, H3N2, and avian in-
fluenza H5N1.Optimized annealing temperature for multiplex DPO PCR
For most conventional PCR methods, a lower annealing
temperature gives a higher sensitivity, which might in-
crease the nonspecific amplification rate [5,12]. However,
if the Tm is increased to maintain high specificity, then
Table 3 Clinical specimens tested by qPCR and multiplex DPO PCR
Positive influenza A Positive
influenza B
Negative
samplesSeasonal H1N1 2009 pandemic H1N1 H3N2 H5N1
RT-qPCR 14 39 29 2 69 80
Multiplex DPO PCR 13 25 16 2 43 134
Positive Concordant Percentage 56 (66.67%, 56/84) 43(62.32%, 43/69) ____
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when the Tm reached 60°C, no nonspecific amplification
was observed and the test was shown to be highly sensi-
tive compared with the other methods tested.
Multiplex DPO PCR is sensitive and specific for the
detection of influenza A and B
Template concentrations as low as 102 viral particles/ml
were detectable using this method, with a robust test re-
sult obtained by multiplex DPO PCR at a concentration
of 103 viral particles/ml when applied to a mixture of
influenza virus templates. A previous study reported the
sensitivity of 102 copies per reaction for each type of virus;
however, the concentration of the mixture of viruses amp-
lified was not stated [5,6]. The DPO primer amplified
PCR products for seasonal H1N1, 2009 pandemic H1N1,
H3N2 and avian influenza H5N1 were clearly visualized
by agarose gel electrophoresis without non-specific ampli-
fication or false-positive bands (Figure 3).
Test specificity was investigated in three ways. Each
DPO primer pair was individually applied towards amp-
lifying a pooled mixture of the five influenza viruses
tested, and a single distinct band was produced for each
template (Figure 4A). Secondly, a multiplex PCR primer
pool was applied towards amplifying each target tem-
plate individually, and yet again, no non-specific bands
were detected (Figure 4B). Furthermore, no non-specificFigure 6 The selected result of clinical samples by qPCR. Selected 45 samplification was observed when applying the multiplex
DPO PCR primers to other, non-targeted virus templates
(Figure 4C). A previous study stated that the DPO system
prevents non-specific amplification without inhibiting the
efficient amplification of the target bands [11]. In this
study, the high sensitivity and specificity were consistent
with previous studies [5,6].
Evaluation of DPO PCR performance to detect viruses in
clinical specimens
This study evaluated the multiplex DPO PCR system
and compared it with qPCR using 233 respiratory clinical
specimens. All clinical samples were screened by single-
plex qPCR for the separate detection of influenza A
and B. Positive specimens were defined as those reach-
ing a florescent threshold value (Cq < 35), and were used
as standards. Based on the statistical results, the multiplex
DPO PCR showed no significant difference in sensitivity
or specificity with conventional single PCR, and had a
higher sensitivity and specificity than the colloidal gold
immunochromatographic assay.
Several previous studies have evaluated different respira-
tory virus diagnostic tests using the DPO-based commer-
cial kit including Seeplex® RV15 ACE Detection kit and
RV 12 Detection kit (Seegene). Their results indicated that
the sensitivity and specificity of the Seeplex DPO based
PCR system were 83.3% and 95.2%, respectively [12]. Chocreening results for influenza A and B detection using qPCR.
Figure 7 The selected result of clinical samples by immunochromatographic assay. Selected result screening for influenza A from 9 clinical
samples. P: positive control; N: negative control.
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RV15 DPO PCR for influenza A were 93% and 99.9%, re-
spectively, and for influenza B were 80% and 99.9%, re-
spectively [13]. Previous studies only used nasopharyngeal
swabs or nasal washs, but not oropharyngeal swabs, as
their main clinical sample types. The variation in sensi-
tivity and specificity of influenza virus detection between
this study and previous studies might be due to different
patient sampling sites, which might result in different
virus loads between the two sample panels. Commonly
used clinical specimens for the detection of respiratory
viruses are oropharyngeal swabs, nasopharyngeal swabs,
nasal washees and sputum. However, different sampling
methods may give rise to a change in the detection of influ-
enza virus sensitivity. Li et al. indicated that nasopharyngealFigure 8 Comparison of three different PCR methods for all influenza
samples detected by DPO PCR; clear bars represent real time PCR positive
detected by immunochromatographic test (ICT), respectively.swab samples may be the most effective alternative to nasal
washes and oropharyngeal swab samples for the examin-
ation of respiratory viruses in adults [14,15]. Another study
also suggested that the use of nasopharyngeal swabs was
superior to oropharyngeal swabs for the detection of influ-
enza viruses by PCR [16]. Indeed, the determination of the
correct sampling site for collection of clinical specimens
might be the most important factor affecting the success-
ful detection of influenza viruses.
Comparison between DPO PCR and qPCR, conventional
single-target PCR and immunochromatographic assay
In this study, no significant difference in sensitivity was
observed between DPO PCR and conventional PCR. Al-
though the use of conventional primer has a low cost andA and B samples. Shaded bars represent the number of positive
samples, conventional PCR positive samples (cPCR), and positives
Figure 9 Comparison of DPO PCR and qPCR positive samples for sH1N1, H1N1pdm09, H3N2, H5N1 and FluB. Shaded bars represent the
number of positive samples detected by DPO PCR; clear bars represent qPCR positive samples.
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proach often produces false positive results with low sen-
sitivity and specificity. The use of conventional primers
has a number of disadvantages including primer competi-
tion, primer dimers and varing anealing temperatures re-
quired for different primers. The current use of multiplex
conventional PCR requires further validation including
nested PCR or probe hybridization assay to verify the
results [17].
In addition to the use of PCR methods, the rapid de-
tection of influenza virus can also be carried out using
the immune colloidal gold technique supplied as com-
mercial kits. The current study demonstrated that this
rapid detection method had the lowest sensitivity andFigure 10 Comparison of positive results between DPO and qPCR in
positive samples detected by DPO PCR; clear bars represent qPCR positivespecificity for virus detection when compared with the
three different PCR based methods (Figure 8).
Although qPCR is usually used as a gold standard in
most laboratories to detect influenza virus, the stan-
dard Cq value should be approximately 35 to determine
a positive outcome as suggested by the World Health
Organization [10]. However, the World Health Orga-
nization strongly suggests that the assay should be re-
peated to verify the diagnostic result if the Cq value is
in the range 30–35 as determined by qPCR [10]. From
the comparative study of positive specimens detected
by qPCR and multiplex DPO PCR in this study, 89.3%
of influenza A positive specimens were observed at a
higher Cq range (30 < Cq < 35). The analytic resultsthree different Cq ranges. Shaded bars represent the number of
samples.
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were in the Cq range from 30 to 35 (Figure 10). The
high percentage of qPCR positive specimens not de-
tected by multiplex DPO PCR might have had a low
target concentration or were degraded by re-freezing of
the sample [4].
Limitations
The multiplex DPO PCR has some limitations. Most stud-
ies consider virus cultures and qPCR as a gold standard
for influenza virus detection. In this study, virus culture
was not available for use for all the influenza viruses
detected.
Conclusions
In conclusion, the optimized multiplex DPO PCR assay
provides reliable sensitivity and specificity for the detec-
tion of seasonal H1N1, 2009 pandemic H1N1, H3N2, in-
fluenza B and avian influenza H5N1. Furthermore, the
sensitivity of DPO PCR was higher than for the immuno-
chromatographic assay, lower than for qPCR and similar
to conventional single PCR for the detection of influenza
A and B. Multiplex DPO PCR is cost-effective, has a short
running time and low technical requirements indicating
its significant potential for influenza virus detection, early
diagnosis and treatment in clinical laboratories.
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